Vidac Pharma Holding Plc (HAM:T9G)

Market Cap	21.99M
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Open	0.5680
Previous Close	0.5500
Day's Range	0.5680 - 0.5680
52-Week Range	0.4500 - 0.8000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Vidac Pharma Holding

Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of medicines for oncologic and dermatologic diseases. The company is developing VDA-1102 ointment, an anti-neoplastic agent that is in Phase 2 clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplastic agent; and VDA-1275, a potent small molecule new chemical entity that are in preclinical stage for use in the treatment of solid tumors. The company...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2021
• Country: United Kingdom
• Stock Exchange: Hamburg Stock Exchange
• Ticker Symbol: T9G

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 15, 2026

Data Sources Report a data error